These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24092964)

  • 1. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study.
    Rakic JM; Leys A; Brié H; Denhaerynck K; Pacheco C; Vancayzeele S; Hermans C; Macdonald K; Abraham I
    Clin Ophthalmol; 2013; 7():1849-58. PubMed ID: 24092964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study.
    Oshima Y; Ishibashi Y; Umeda N; Nagata T; Yoshida S; Uchio E; Kondo H; Sonoda KH; Ishibashi T
    BMC Ophthalmol; 2021 Jan; 21(1):58. PubMed ID: 33485320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration.
    van Asten F; Evers-Birkenkamp KU; van Lith-Verhoeven JJ; de Jong-Hesse Y; Hoppenreijs VP; Hommersom RF; Scholten AM; Hoyng CB; Klaver JH;
    Acta Ophthalmol; 2015 Mar; 93(2):126-33. PubMed ID: 25488348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
    Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
    Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
    Yuzawa M; Fujita K; Wittrup-Jensen KU; Norenberg C; Zeitz O; Adachi K; Wang EC; Heier J; Kaiser P; Chong V; Korobelnik JF
    Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study.
    Bertelmann T; Feltgen N; Scheffler M; Hufenbach U; Wiedon A; Wilhelm H; Ziemssen F
    Health Qual Life Outcomes; 2016 Sep; 14(1):132. PubMed ID: 27644469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
    JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study.
    Holz FG; Minnella AM; Tuli R; Yoganathan P; Parikh S; Hamilton R;
    PLoS One; 2020; 15(12):e0244183. PubMed ID: 33378369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vision-related quality of life in Japanese patients with wet age-related macular degeneration treated with intravitreal aflibercept in a real-world setting.
    Gomi F; Migita H; Sakaguchi T; Okada H; Sugawara T; Hikichi Y;
    Jpn J Ophthalmol; 2019 Nov; 63(6):437-447. PubMed ID: 31673841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab.
    Nixon DR; Flinn NA
    Clin Ophthalmol; 2017; 11():715-721. PubMed ID: 28458510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
    Mitchell P; Bandello F; Schmidt-Erfurth U; Lang GE; Massin P; Schlingemann RO; Sutter F; Simader C; Burian G; Gerstner O; Weichselberger A;
    Ophthalmology; 2011 Apr; 118(4):615-25. PubMed ID: 21459215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity.
    Monés J; Biarnés M; Trindade F; Casaroli-Marano R
    Graefes Arch Clin Exp Ophthalmol; 2012 Dec; 250(12):1737-44. PubMed ID: 22527314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.
    Finger RP; Wiedemann P; Blumhagen F; Pohl K; Holz FG
    Acta Ophthalmol; 2013 Sep; 91(6):540-6. PubMed ID: 23171290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study.
    Wu WC; Chen JT; Tsai CY; Wu CL; Cheng CK; Shen YD; Tsai A; Wu PC
    BMC Ophthalmol; 2020 Nov; 20(1):462. PubMed ID: 33238968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of Razumab™ (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study.
    Sharma S; Gupta V; Maiti A; Natesh S; Saxena S; Dave V; Parmar V; Sampangi R; Murthy H; Dharwadkar S; Yadav NK; Joshi S; Mayor R; Ratra D; Basu S; Goel N; Chaturvedi A; Patel R; Jose V
    Int J Retina Vitreous; 2021 Mar; 7(1):24. PubMed ID: 33762008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity.
    Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group
    Ophthalmology; 2014 May; 121(5):1092-101. PubMed ID: 24461586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) in a Norwegian population of patients with neovascular age-related macular degeneration compared to a control population.
    Jelin E; Wisløff T; Moe MC; Heiberg T
    Health Qual Life Outcomes; 2019 Aug; 17(1):140. PubMed ID: 31412873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.